6533b86efe1ef96bd12cbe87
RESEARCH PRODUCT
Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease
Olivier GovaereSine Kragh PetersenNuria Martinez-lopezJasper WoutersMatthias Van HaeleRosellina M. MancinaOveis JamialahmadiOrsolya Bilkei-gorzoPierre Bel LassenRebecca DarlayJulien PeltierJeremy M. PalmerRamy YounesDina TiniakosGuruprasad P. AithalMichael AllisonMichele VaccaMelker GöranssonMichael J. DrinnanHannele Yki-järvinenJean-francois DufourMattias EkstedtSven FrancqueSalvatore PettaElisabetta BugianesiJörn M SchattenbergChristopher P. DayHeather J. CordellBaki TopalKarine ClémentStefano RomeoVlad RatziuTania RoskamsAnn K. DalyQuentin M. AnsteeMatthias TrostAnetta Härtlovasubject
0303 health sciencesmedicine.medical_specialtyLipopolysaccharidebusiness.industryFatty liverInflammationmedicine.disease3. Good healthMSR1Pathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologychemistryFibrosisInternal medicineMedicine030211 gastroenterology & hepatologySteatohepatitismedicine.symptomSteatosisbusiness030304 developmental biologydescription
AbstractObesity-associated inflammation is a key player in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the exact mechanisms remain incompletely understood. Here we demonstrate that macrophage scavenger receptor 1 (MSR1, CD204) expression is associated with the occurrence of hepatic lipid-laden foamy macrophages and correlates with the degree of steatosis and steatohepatitis in a cohort of 170 NAFLD patients. Mice lacking Msr1 are protected against high fat-cholesterol diet (HFD)-induced metabolic disorder, showing fewer hepatic lipid-laden foamy macrophages, less hepatic inflammation, improved dyslipidemia and glucose tolerance, while showing a change in hepatic lipid metabolism. We show that MSR1 induces a pro-inflammatory response via the JNK signaling pathway upon triggering by saturated fatty acids. In vitro blockade of the receptor prevented the accumulation of lipids in primary macrophages which inhibited the switch towards a pro-inflammatory phenotype and the release of cytokines such as TNFa. Targeting MSR1 using monoclonal antibody therapy in an obesity-associated NAFLD mouse model and ex vivo human liver slices resulted in the prevention of foamy macrophage formation and liver inflammation. Moreover, we identified that rs41505344, a polymorphism in the upstream transcriptional region of MSR1, was associated with altered serum triglycerides and aspartate transaminase levels in a cohort of over 400,000 patients. Taken together, our data suggest a critical role for MSR1 in lipid homeostasis and a potential therapeutic target for the treatment of NAFLD.One Sentence SummaryThe immunometabolic role of MSR1 in human NAFLD.
year | journal | country | edition | language |
---|---|---|---|---|
2020-02-02 |